Biocon Gives Clarification on Clinical Study of Itolizumab for COVID-19 after Backlash - IndiaMedToday
Phase 3 clinical trial waived off for Biocon's COVID-19 drug
Biocon KGI Certificate Program in Clinical Development - Biocon Academy
सिद्धार्थ on Twitter: "Brief summary here: 👉 Biocon Biologics had submitted result to https://t.co/pXvPY9Oaef @NIH on Aug 02, 2020 BUT results were returned after quality control review on Aug 10, 2020. On
Two Biocon biosimilar drugs enter global clinical trials | Mint
Infographic: Biocon opens this year with a stellar performance reporting 71% growth in profits | AlphaStreet
Webinar on Bench to Bedside: How Clinical Trials Work in Drug Development
What is the controversy regarding Biocon's COVID-19 drug Itolizumab? - Quora
Strategic Management Analysis of Biocon India Group Limited - CIRCLE OF BUSINESS Strategic Management Analysis of Biocon India Group Limited
Research & Development - Biocon - Global Biopharmaceutical company
Sales of Biocon's itolizumab surge as phase-4 clinical trials begin - Rediff.com Business
Biocon Biologics' itolizumab gets DCGI nod for emergency use to treat covid-19 | Mint
List of Clinically Tested Oral Insulin Formulations. | Download Table
Biocon, Quark to start clinical tests for eye disorder drug | Mint
Biocon Ltd Clinical Trials - GlobalData
Biocon - Wikipedia
Biocon forced to move clinical trials out of India | Business Standard News
India ruling on drug trials injects fears for industry's health | Financial Times
CBI arrests Joint drug controller for allegedly taking Rs. 4 lakh bribe to clear Biocon Biologics's diabetes injection; company denies | The Financial Express
Biocon's coronavirus drug for emergency use given approval after trial on only 30 patients - India News
Biocon Biologics enters strategic collaboration with Serum Institute unit - Pharmaceutical Technology
Biocon Business
Biocon's Itolizumab Drug For Emergency Use on COVID-19 Patients Gets Approval After Clinical Trial on 30 Patients Across Only 4 Hospitals | 📰 LatestLY
Biocon founder Kiran Mazumdar Shaw says India's Covid-19 vaccine will enter clinical trials in 9 months
